Table 6 Mulitvariate analysis for prediction of recurrence adjusted for results of cytology, time interval between last NMIBC and urine sampling and European Organization for Research and Treatment of Cancer (EORTC) risk groups
Model 1 (Cytology) | Model 2 (Cytology & FISH) | Model 3 (Cytology& uCyt+) | Model 4 (Cytology & NMP22) | |||||
|---|---|---|---|---|---|---|---|---|
Hazard ratio | p | Hazard ratio | p | Hazard ratio | p | Hazard ratio | p | |
Cytology | 2.8 (1.2-7.0) | .02 | 2.2 (0.8-6.3) | .13 | 1.9 (0.7-5.1) | .18 | 2.6 (1.0-6.5) | .04 |
FISH | 1.6 (0.6-4.6) | .34 | ||||||
uCyt+ | 3.23 (1.2-8.7) | .01 | ||||||
NMP22 | 3.1 (1.2-8.6) | .01 | ||||||
Last tumor < vs. > 6 months | 3.6 (1.5-8.9) | .001 | 3.8 (1.6-9.6) | .003 | 4.2 (1.7-11.0) | .002 | 3.0 (1.2-7.9) | .01 |
History of low/intermediate vs. high risk urothelial carcinoma | 1.2 (0.5-2.9) | .83 | 1.1 (0.5-2.7) | .72 | 1.4 (0.5-3.5) | .51 | 1.2 (0.5-3.2) | .64 |